Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response

癌症研究 肝癌 医学 肿瘤科 癌症 内科学 肝细胞癌
作者
Stefano Caruso,Anna-Line Calatayud,Jill Pilet,Tiziana La Bella,Samia Rekik,Sandrine Imbeaud,Éric Letouzé,Léa Meunier,Quentin Bayard,Nataliya Rohr‐Udilova,Camille Péneau,Bettina Grasl‐Kraupp,Leanne de Koning,Bérengère Ouine,Paulette Bioulac‐Sage,Gabrielle Couchy,Julien Caldéraro,Jean‐Charles Nault,Jessica Zucman‐Rossi,Sandra Rebouissou
出处
期刊:Gastroenterology [Elsevier BV]
卷期号:157 (3): 760-776 被引量:205
标识
DOI:10.1053/j.gastro.2019.05.001
摘要

BACKGROUND AND AIMS: Hepatocellular carcinomas (HCCs) are heterogeneous aggressive tumors with low rates of response to treatment at advanced stages. We screened a large panel of liver cancer cell lines (LCCLs) to identify agents that might be effective against HCC and markers of therapeutic response. METHODS: We performed whole-exome RNA and microRNA sequencing and quantification of 126 proteins in 34 LCCLs. We screened 31 anticancer agents for their ability to decrease cell viability. We compared genetic, RNA, and protein profiles of LCCLs with those of primary HCC samples and searched for markers of response. RESULTS: The protein, RNA and mutational signatures of the LCCLs were similar to those of the proliferation class of HCC, which is the most aggressive tumor type. Cell lines with alterations in genes encoding members of the Ras-MAPK signaling pathway and that required fibroblast growth factor (FGF)19 signaling via FGF receptor 4 for survival were more sensitive to trametinib than to FGF receptor 4 inhibitors. Amplification of FGF19 resulted in increased activity of FGF19 only in tumor cells that kept a gene expression pattern of hepatocyte differentiation. We identified single agents and combinations of agents that reduced viability of cells with features of the progenitor subclass of HCC. LCCLs with inactivating mutations in TSC1 and TSC2 were sensitive to the mammalian target of rapamycin inhibitor rapamycin, and cells with inactivating mutations in TP53 were sensitive to the Aurora kinase A inhibitor alisertib. Amplification of MET was associated with hypersensitivity to cabozantinib and the combination of sorafenib and inhibitors of MAP kinase 1 and MAP kinase2 had a synergistic antiproliferative effect. CONCLUSION: LCCLs can be screened for drugs and agents that might be effective for treatment of HCC. We identified genetic alterations and gene expression patterns associated with response to these agents. This information might be used to select patients for clinical trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
李爱国的应助被瘦瘦的紫翠采纳,获得10
1秒前
2秒前
伯赏夜南完成签到,获得积分10
3秒前
3秒前
3秒前
3秒前
YK完成签到,获得积分10
3秒前
4秒前
Crazy_Diamond的应助被融融虫采纳,获得50
4秒前
雪山大地发布了新的文献求助10
5秒前
何hehe发布了新的文献求助10
5秒前
5秒前
5秒前
刻苦夜雪发布了新的文献求助10
5秒前
5秒前
胡萝卜z完成签到 ,获得积分10
6秒前
6秒前
snn发布了新的文献求助10
6秒前
小明同学发布了新的文献求助10
6秒前
7秒前
慕青的应助被杨苗苗采纳,获得10
7秒前
7秒前
大睡神发布了新的文献求助10
8秒前
8秒前
8秒前
高高的冷玉完成签到,获得积分10
8秒前
9秒前
zxp的应助被王政采纳,获得10
9秒前
hw发布了新的文献求助10
10秒前
nike胡咧咧完成签到,获得积分10
10秒前
10秒前
whg发布了新的文献求助10
11秒前
XHCZ发布了新的文献求助10
11秒前
11秒前
ccc发布了新的文献求助20
11秒前
橙子发布了新的文献求助10
12秒前
杨lan完成签到 ,获得积分10
13秒前
kkyy发布了新的文献求助10
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163835
求助须知:如何正确求助?哪些是违规求助? 9557925
关于积分的说明 21742693
捐赠科研通 7754454
什么是DOI,文献DOI怎么找? 3428350
关于科研通互助平台的介绍 2553034
邀请新用户注册赠送积分活动 2472982